A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer

Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized the safety, tolerability, and efficacy of SMK Therapy in subjects with advanced metastatic cancer. Methods All s...

Descripción completa

Detalles Bibliográficos
Autores principales: Stega, Jeanetta, Noel, Marcus S., Vandell, Alexander G., Stega, Damian, Del Priore, Giuseppe, Hoffman, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066285/
https://www.ncbi.nlm.nih.gov/pubmed/30929156
http://dx.doi.org/10.1007/s10637-019-00758-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066285/
https://www.ncbi.nlm.nih.gov/pubmed/30929156
http://dx.doi.org/10.1007/s10637-019-00758-8

Ejemplares similares